PCOS Is Now PMOS. Here's Why the Name Change Matters More Than You Think.
Vicki Powell
Co-Founder and CEO of Lume Health
3 min read
As you may have already seen, Polycystic ovary syndrome (PCOS) has just been officially renamed!
On May 12, 2026, a paper published in The Lancet announced that the condition will now be called polyendocrine metabolic ovarian syndrome - PMOS.
That one letter change is really meaningful for a lot of women we talk to.
Words are powerful in shaping how people understand their bodies, how doctors diagnose, and how science frames its questions. And for a condition affecting 1 in 8 women worldwide - more than 170 million people - a better name was well overdue.
Why PCOS Was Always a Misnomer
The old name was confusing.
"Polycystic" implies pathological ovarian cysts. But the visible structures on ultrasound in this condition are not cysts at all, they are arrested follicles. Many people with the syndrome have no visible ovarian abnormalities whatsoever. Yet for decades, a clear ultrasound could lead to a dismissed diagnosis, even in patients presenting with every other symptom of the condition.
The consequences were significant. Research suggests that up to 70% of people with the condition remain undiagnosed. Delayed diagnosis often meant years without treatment for insulin resistance, elevated androgens, inflammation, and disrupted reproductive cycles.
What the New Name Actually Means
PMOS — polyendocrine metabolic ovarian syndrome — breaks down like this:
Polyendocrine acknowledges that multiple hormonal systems are involved simultaneously: insulin, androgens, cortisol, and neuroendocrine signalling all interact in this condition. It is not a single-hormone problem.
Metabolic recognizes that the condition's systemic reach extends well beyond the reproductive system. Insulin resistance, dyslipidemia, cardiovascular risk, and weight dysregulation are central features of PMOS.
Ovarian retains the reproductive dimension of the syndrome, while no longer implying that cysts are the defining characteristic.
Taken together, PMOS is a name that points clinicians and patients toward the right questions from the start.
This Is a System-Level Condition, Not Just a Reproductive One
If you've read our previous blog on circadian rhythm disruption and PCOS, you'll know that we've long argued for viewing this condition through a wider lens.
PMOS is not primarily a disorder of ovaries. It is a disorder of physiological coordination, across hormonal axes, metabolic systems, and circadian timing.
Consider how many of its features cluster around disrupted regulatory rhythms:
Cortisol dysregulation. Abnormal hypothalamic–pituitary–adrenal (HPA) axis activity is well-documented in PMOS. Flattened cortisol amplitude both reflects and reinforces the condition's hormonal environment.
Insulin resistance. Chronically elevated or mistimed cortisol reduces insulin sensitivity and drives excess androgen production from the ovaries. This is not a coincidence — it is a mechanistic chain.
Sleep disruption. Poor sleep, delayed sleep timing, and chronic fatigue are reported disproportionately by people with PMOS, independent of BMI. Sleep disturbances further blunt cortisol amplitude, reinforcing the cycle.
Inflammation. Flattened cortisol rhythms are associated with elevated baseline inflammation — another common feature of the syndrome.
The picture that emerges is not one of a single broken hormone. It is a picture of a system that has lost its timing.
The Process Behind the Rename
The consensus process involved 56 leading academic, clinical, and patient organizations, and drew on more than 22,000 survey responses from patients, clinicians, and researchers across all world regions, gathered over more than a decade of iterative consultation.
Priorities included scientific accuracy, clarity, cultural appropriateness, stigma reduction, and implementation feasibility. Multiple candidate names were evaluated before PMOS emerged as the near-unanimous choice.
A three-year transition period is now underway, supported by international education campaigns targeting clinicians, governments, and researchers. Clinical guidelines, medical education, and international disease classification systems - including ICD codes - will all be updated.
What This Means in Practice
For people with PMOS, the most immediate change is framing.
A diagnosis that centers "cysts" and "ovaries" leads some patients to treat it primarily as a gynecological problem, addressed through contraceptives or fertility interventions. A diagnosis named PMOS points immediately toward insulin, metabolism, hormonal axes, and long-term cardiometabolic risk. The management conversation changes.
It also signals that light, circadian timing, and cortisol regulation — inputs that directly shape the hormonal environment — deserve a seat at the table. These are not complementary add-ons to PMOS care. They address the physiological substrate.
A Different Way to Think About PMOS
The rename is not just bureaucratic housekeeping.
It reflects a genuine scientific shift in how we understand a condition that medicine has historically underserved. For too long, the diagnosis hinged on an ultrasound finding that many patients don't even have, while its metabolic and neuroendocrine complexity went undertreated.
PMOS is a condition rooted in dysregulated hormonal timing. Cortisol rhythms, insulin sensitivity, androgen production, sleep architecture — these do not operate in isolation. They are part of a circadian system that, when disrupted, amplifies dysfunction across every one of these axes simultaneously.
At Lume, we’re excited to see medicine and language being updated finally, for groups of people who have been underserved for a long time.
We’re building a wearable cortisol monitor that we hope will play a role in further exploring and defining these conditions in the future.
References:
Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00717-8.
Heydari, T. and Ramdass, P.V.A.K. (2025) 'Circadian rhythm disruption and polycystic ovary syndrome: A systematic review and meta-analysis', AJOG Global Reports, 5(2), p. 100479. doi:10.1016/j.xagr.2025.100479.
Kodaman, P.H. and Duleba, A.J. 'Metabolic and endocrine effects of statins in polycystic ovary syndrome', Contemporary Endocrinology, pp. 241–258. doi:10.1007/978-1-59745-108-6_15.
